LitAlert ~~ GeneLit.com

    • Physicians' experience, practice and education, on genetic testing and genetic counseling: a nationwide survey study in Greece.
    • Fountzilas E, Apostolou P, Vasiliadis AV, Aivazi D, Saloustros E, Fostira F.
    • Fam Cancer. 2022 Jan 24. doi: 10.1007/s10689-022-00290-4. Epub ahead of print.
    • The first case report of a patient with oligodendroglioma harboring CHEK2 germline mutation.
    • Li X, Xue H, Luo N, Han T, Li M, Jia D.
    • Front Genet. 2022 Jan 24;12:718689. doi: 10.3389/fgene.2022.718689.
    • Analysis of BRCA germline mutations in Chinese prostate cancer patients.
    • Chen W, Xia W, Xue S, Huang H, Lin Q, Liu T, Zhang Y, Dong B, Yu Z.
    • Front Oncol. 2022 Jan 24;10:746102. doi: 10.3389/fonc.2022.746102.
    • Exceptional response to lurbinectedin and irinotecan in BRCA-mutated platinum-resistant ovarian cancer patient: a case report.
    • Cortesi L, Venturelli M, Barbieri E, Baldessari C, Bardasi C, Coccia E, Baglio F, Rimini M, Greco S, Napolitano M, Pipitone S, Dominici M.
    • Ther Adv Chronic Dis. 2022 Jan 13;13:20406223211063023. doi: 10.1177/20406223211063023.
    • Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report.
    • Rubinson D, Wolpin BM, Warsofsky IS, Ryan DP, Perez K, Rahma O, Singh H, Yurgelun MB, Shapiro GI, Aguirre AJ, D'Andrea AD, Cleary JM.
    • J Gastrointest Oncol. 2021 Dec;12(6):3133-3140. doi: 10.21037/jgo-21-197.
  • LitAlert ~~ GeneLit.com

    • Association of Interleukin-10 Polymorphism (rs1800896, rs1800871, and rs1800872) with Breast Cancer Risk: An Updated Meta-Analysis based on different ethnic groups.
    • Li L, Xiong W, Li D, Cao J.
    • Front Genet. 2022 Jan 21;12:829283. doi: 10.3389/fgene.2022.829283.
    • The Mutational Landscape of Early-Onset Breast Cancer: A Next-Generation Sequencing Analysis.
    • Andrikopoulou A, Chatzinikolaou S, Kyriopoulos I, Bletsa G, Kaparelou M, Liontos M, Dimopoulos MA, Zagouri F.
    • Front Oncol. 2022 Jan 21;10:797505. doi: 10.3389/fonc.2021.797505.
    • Hyperthermic intraperitoneal chemotherapy (HIPEC) after primary debulking surgery in advanced epithelial ovarian cancer: Is BRCA mutational status making the difference?
    • Ghirardi V, De Felice F, D'Indinosante M, Bernardini F, Giudice MT, Fagotti A, Scambia G.
    • Cancer Treat Res Commun. 2022 Jan 14;31:100518. doi: 10.1016/j.ctarc.2022.100518. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 6: Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes.
    • Palicelli A, Croci S, Bisagni A, Zanetti E, De Biase D, Melli B, Sanguedolce F, Ragazzi M, Zanelli M, Chaux A, Cañete-Portillo S, Bonasoni MP, Ascani S, De Leo A, Giordano G, Landriscina M, Carrieri G, Cormio L, Gandhi J, Nicoli D, Farnetti E, Piana S, Tafuni A, Bonacini M.
    • Biomedicines. 2022 Jan 22;10(2):236. doi: 10.3390/biomedicines10020236.
    • Association of genetic ancestry and molecular signatures with cancer survival disparities: a pan-cancer analysis.
    • Lee KK, Rishishwar L, Ban D, Nagar SD, Mariño-Ramírez L, McDonald JF, Jordan IK.
    • Cancer Res. 2022 Jan 21:canres.CAN-21-2105-A.2021. doi: 10.1158/0008-5472.CAN-21-2105. Epub ahead of print.
    • Pregnancy after breast cancer in BRCA1/2 mutation carriers.
    • Maksimenko J, Irmejs A, Gardovskis J.
    • Hered Cancer Clin Pract. 2022 Jan 21;20(1):3. doi: 10.1186/s13053-022-00209-1.
    • Molecular Features and Clinical Management of Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer.
    • Kasuga A, Okamoto T, Udagawa S, Mori C, Mie T, Furukawa T, Yamada Y, Takeda T, Matsuyama M, Sasaki T, Ozaka M, Ueki A, Sasahira N.
    • Int J Mol Sci. 2022 Jan 21;23(13):1205. doi: 10.3390/ijms23031205.
    • Malignant prediction of incidental findings using ring-type dedicated breast positron emission tomography.
    • Sasada S, Masumoto N, Emi A, Kadoya T, Okada M.
    • Sci Rep. 2022 Jan 21;12(1):1144. doi: 10.1038/s41598-022-05166-2.
    • Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.
    • Xia YY, Gronwald J, Karlan B, Lubinski J, McCuaig JM, Brooks J, Moller P, Eisen A, Sun S, Senter L, Bordeleau L, Neuhausen SL, Singer CF, Tung N, Foulkes WD, Sun P, Narod SA, Kotsopoulos J; Hereditary Ovarian Cancer Clinical Study Group.
    • Gynecol Oncol. 2022 Jan 18:S0090-8258(22)00022-1. doi: 10.1016/j.ygyno.2022.01.014. Epub ahead of print.
    • Remote AI Supported E-Multidisciplinary Oncology Conference in Breast Cancer as a Technology and Method to Optimize Outcomes in the Peripheries.
    • Mammas CS, Mamma AS, Papaxoinis G, Georgiou I.
    • Stud Health Technol Inform. 2022 Jan 14;289:309-312. doi: 10.3233/SHTI210921.
  • LitAlert ~~ GeneLit.com

    • Evaluating mismatch repair status to screen clinical advanced breast carcinomas for immunotherapy: experience from a large academic institution.
    • Arole V, Shafi S, Challa B, Parwani AV, Tozbikian G, Li Z.
    • Clin Breast Cancer. 2022 Jan 21:S1526-8209(22)00022-2. doi: 10.1016/j.clbc.2022.01.010. Epub ahead of print.
    • Development and pilot testing of an online decision aid for women considering risk-stratified breast screening.
    • Lippey J, Keogh L, Campbell I, Mann GB, Forrest L.
    • J Community Genet. 2022 Jan 21. doi: 10.1007/s12687-021-00571-y. Epub ahead of print.
    • 11 ESMO 2021 breakthroughs: practicing oncologist's perceptions on data presentation.
    • van Halteren HK, Tan A, Pellegrino B, Brasiuniene B, Bennouna J, Cunquero-Tomás AJ, Strijbos M; ESMO Practicing Oncologists Working Group.
    • ESMO Open. 2022 Jan 17;7(1):100376. doi: 10.1016/j.esmoop.2021.100376. Epub ahead of print.
    • Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.
    • Cheng B, Pan W, Xing Y, Xiao Y, Chen J, Xu Z.
    • Eur J Med Chem. 2022 Jan 12;230:114109. doi: 10.1016/j.ejmech.2022.114109. Epub ahead of print.
    • Review
    • Prediction of breast cancer risk based on flow variant analysis of circulating peripheral blood mononuclear cells.
    • Loke J, Alim I, Yam S, Klugman S, Xia LC, Gruber D, Tegay D, LaBella A, Onel K, Ostrer H.
    • HGG Adv. 2022 Jan 7;100085. doi: 10.1016/j.xhgg.2022.100085. Epub ahead of print.
    • Clinical validation of genomic functional screen data: analysis of observed BRCA1 variants in an unselected population cohort.
    • Schiabor Barrett KM, Masnick M, Hatchell KE, Savatt JM, Banet N, Buchanan A, Willard HF.
    • HGG Adv. 2022 Jan 7;100086. doi: 10.1016/j.xhgg.2022.100086. Epub ahead of print.
    • Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology.
    • Shah SM, Demidova EV, Lesh RW, Hall MJ, Daly MB, Meyer JE, Edelman MJ, Arora S.
    • Cancer Treat Rev. 2022 Jan 5;104:102337. doi: 10.1016/j.ctrv.2021.102337. Epub ahead of print.
    • The Value of Tyrer-Cuzick Versus Gail Risk Modeling in Predicting Benefit from Screening MRI in Breast Cancer.
    • Sevdalis A, Deng X, Bandyopadhyay D, McGuire KP.
    • Eur J Breast Health. 2021 Dec 30 [eCollection 2022 Jan];18(1):79-84. doi: 10.4274/ejbh.galenos.2021.2021-8-2.
    • Can Social Media Be Used as a Community-Building and Support Tool among Jewish Women Impacted by Breast and Ovarian Cancer? An Evidence-Based Observational Report.
    • Dunn C, Campbell S, Marku N, Fleischmann A, Silber E, Rosen M, Tercyak KP.
    • Healthcare (Basel). 2021 Dec 28;10(1):51. doi: 10.3390/healthcare10010051.
  • LitAlert ~~ GeneLit.com

    • Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.
    • Schrijver LH, Mooij TM, Pijpe A, Sonke GS, Mourits MJE, Andrieu N, Antoniou AC, Easton DF, Engel C, Goldgar D, John EM, Kast K, Milne RL, Olsson H, Phillips KA, Terry MB, Hopper JL, van Leeuwen FE, Rookus MA.
    • J Natl Cancer Inst. 2022 Jan 20:djac004. doi: 10.1093/jnci/djac004. Epub ahead of print.

    Commentary:

    Oral Contraceptives and BRCA Cancer: A Balancing Act.

    • Redefining and expanding the sphere of influence of BRCA in breast and colorectal cancers and beyond.
    • Lou E.
    • Oncotarget. 2022 Jan 14;13:120-121. doi: 10.18632/oncotarget.28164.

    Original research:

    Opposing effects of BRCA1 mRNA expression on patient survival in breast and colorectal cancer and variations among African American, Asian, and younger patients.

    • Characteristics and experiences of patients from a community-based and consumer-directed hereditary cancer population screening initiative.
    • Greve V, Odom K, Pudner S, Lamb NE, Cooper SJ, East K.
    • HGG Adv. 2021 Aug 24 [eCollection 2022 Jan 13];3(1):100055. doi: 10.1016/j.xhgg.2021.100055.
    • Associations of genetic susceptibility to 16 cancers with risk of breast cancer overall and by intrinsic subtypes.
    • Choi J, Jia G, Wen W, Tao R, Long J, Shu XO, Zheng W.
    • HGG Adv. 2021 Dec 10 [eCollection 2022 Jan 13];3(1):100077. doi: 10.1016/j.xhgg.2021.100077.
    • A whole-exome case-control association study to characterize the contribution of rare coding variation to pancreatic cancer risk.
    • Yu Y, Chang K, Chen JS, Bohlender RJ, Fowler J, Zhang D, Huang M, Chang P, Li Y, Wong J, Wang H, Gu J, Wu X, Schildkraut J, Cannon-Albright L, Ye Y, Zhao H, Hildebrandt MAT, Permuth JB, Li D, Scheet P, Huff CD.
    • HGG Adv. 2021 Dec 10 [eCollection 2022 Jan 13];3(1):100078. doi: 10.1016/j.xhgg.2021.100078.
    • [A Case of Recurrent Breast Cancer with Improving Activities of Daily Living by Olaparib Treatment].
    • Nakagawa T, Oda G, Okamoto K, Ishikawa T, Wakana K, Oshima N.
    • Gan To Kagaku Ryoho. 2021 Dec;48(13):1556-1558. Japanese.
    • Case report. [Article in Japanese]
    • [Two Cases of Hereditary Breast Cancer in Which Genetic Counseling Was Useful].
    • Sasaki A, Nagata T, Okamoto Y, Watanabe M, Saida Y.
    • Gan To Kagaku Ryoho. 2021 Dec;48(13):1589-1591. Japanese.
    • Case report. [Article in Japanese]
    • [A Case of Metastatic Breast Cancer with BRCA1 Mutation after Breast Reconstruction and Pregnancy].
    • Suzuki T, Hashimoto N, Yokoyama K, Yoshida T, Yamauchi Y, Sawano T, Ohashi M, Kimura A, Kato M, Umehara Y, Murata A, Takahash K.
    • Gan To Kagaku Ryoho. 2021 Dec;48(13):1840-1842. Japanese.
    • Case report. [Article in Japanese]
    • [Hereditary Breast and Ovarian Cancer(HBOC)in a Young Adult-A Case Report].
    • Adachi K, Kubota H, Suzuki S, Hirano T, Ishibashi N, Sakurai K.
    • Gan To Kagaku Ryoho. 2021 Dec;48(13):1843-1845. Japanese.
    • Case report. [Article in Japanese]
  • LitAlert ~~ GeneLit.com

    • Case Report: a BRCA2 Mutation Identified through Next Generation Sequencing in a Birt-Hogg-Dubè Syndrome Family.
    • Bandini E, Cangini I, Arcangeli V, Ravegnani M, Andreotti V, Prisinzano G, Pastorino L, Martinelli G, Falcini F, Calistri D, Zampiga V, Danesi R.
    • Front Oncol. 2022 Jan 19;10:835346. doi: 10.3389/fonc.2022.835346.
    • Real-world homologous recombination repair mutation testing in metastatic castration-resistant prostate cancer in the USA, Europe and Japan.
    • Leith A, Ribbands A, Kim J, Last M, Barlow S, Yang L, Ghate SR.
    • Future Oncol. 2022 Jan 19. doi: 10.2217/fon-2021-1113. Epub ahead of print.
    • Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
    • Poveda A, Lheureux S, Colombo N, Cibula D, Lindemann K, Weberpals J, Bjurberg M, Oaknin A, Sikorska M, González-Martín A, Madry R, Rubio Pérez MJ, Ledermann J, Davidson R, Blakeley C, Bennett J, Barnicle A, Škof E.
    • Gynecol Oncol. 2022 Jan 19:S0090-8258(21)01693-0. doi: 10.1016/j.ygyno.2021.12.025. Epub ahead of print.
    • The neglected members of the family: non-BRCA mutations in the Fanconi anemia/BRCA pathway and reproduction.
    • Vanni VS, Campo G, Cioffi R, Papaleo E, Salonia A, Viganò P, Lambertini M, Candiani M, Meirow D, Orvieto R.
    • Hum Reprod Update. 2022 Jan 19:dmab045. doi: 10.1093/humupd/dmab045. Epub ahead of print.
    • Review
    • Rare germline copy number variants (CNVs) and breast cancer risk.
    • Dennis J, Tyrer JP, Walker LC, Michailidou K, Dorling L, Bolla MK, Wang Q, Ahearn TU, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Freeman LEB, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bogdanova NV, Bojesen SE, Brenner H, Castelao JE, Chang-Claude J, Chenevix-Trench G, Clarke CL; NBCS Collaborators, Collée JM; CTS Consortium, Couch FJ, Cox A, Cross SS, Czene K, Devilee P, Dörk T, Dossus L, Eliassen AH, Eriksson M, Evans DG, Fasching PA, Figueroa J, Fletcher O, Flyger H, Fritschi L, Gabrielson M, Gago-Dominguez M, García-Closas M, Giles GG, González-Neira A, Guénel P, Hahnen E, Haiman CA, Hall P, Hollestelle A, Hoppe R, Hopper JL, Howell A; ABCTB Investigators; kConFab/AOCS Investigators, Jager A, Jakubowska A, John EM, Johnson N, Jones ME, Jung A, Kaaks R, Keeman R, Khusnutdinova E, Kitahara CM, Ko YD, Kosma VM, Koutros S, Kraft P, Kristensen VN, Kubelka-Sabit K, Kurian AW, Lacey JV, Lambrechts D, Larson NL, Linet M, Ogrodniczak A, Mannermaa A, Manoukian S, Margolin S, Mavroudis D, Milne RL, Muranen TA, Murphy RA, Nevanlinna H, Olson JE, Olsson H, Park-Simon TW, Perou CM, Peterlongo P, Plaseska-Karanfilska D, Pylkäs K, Rennert G, Saloustros E, Sandler DP, Sawyer EJ, Schmidt MK, Schmutzler RK, Shibli R, Smeets A, Soucy P, Southey MC, Swerdlow AJ, Tamimi RM, Taylor JA, Teras LR, Terry MB, Tomlinson I, Troester MA, Truong T, Vachon CM, Wendt C, Winqvist R, Wolk A, Yang XR, Zheng W, Ziogas A, Simard J, Dunning AM, Pharoah PDP, Easton DF.
    • Commun Biol. 2022 Jan 18;5(1):65. doi: 10.1038/s42003-021-02990-6.
  • LitAlert ~~ GeneLit.com

    • Subfertility, use of fertility treatments and BRCA mutation status and the risk of ovarian cancer.
    • Lerner-Geva L, Chetrit A, Farhi A, Lubin F, Sadezki S; National Israel Ovarian Cancer Study Group.
    • Arch Gynecol Obstet. 2022 Jan 18. doi: 10.1007/s00404-021-06355-6. Epub ahead of print.
    • Expression Profiling in Ovarian Cancer Reveals Coordinated Regulation of BRCA1/2 and Homologous Recombination Genes.
    • Custódio N, Savisaar R, Carvalho C, Bak-Gordon P, Ribeiro MI, Tavares J, Nunes PB, Peixoto A, Pinto C, Escudeiro C, Teixeira MR, Carmo-Fonseca M.
    • Biomedicines. 2022 Jan 18;10(2):199. doi: 10.3390/biomedicines10020199.
    • Clinical benefit with PARP inhibitor for pathogenic germline FANCA-mutated relapsed epithelial ovarian cancer: a case report.
    • Qian B, Lu J, Leng W, Yan Z, Chen S, Yi H, Jiang Z.
    • Front Oncol. 2022 Jan 18;10:778545. doi: 10.3389/fonc.2022.778545.
    • Clinician-Reported Impact of Germline Multigene Panel Testing on Cancer Risk Management Recommendations.
    • Horton C, Blanco K, Lo MT, Speare V, LaDuca H, Dolinsky J, Kurian AW.
    • JNCI Cancer Spectr. 2022 Jan 18; pkac002. doi: 10.1093/jncics/pkac002. eCollection 2022 Jan.
    • Racial and ethnic variation in multigene panel testing in a cohort of BRCA1/2-negative individuals who had genetic testing in a large urban comprehensive cancer center.
    • Tatineni S, Tarockoff M, Abdallah N, Purrington KS, Assad H, Reagle R, Petrucelli N, Simon MS.
    • Cancer Med. 2022 Jan 17. doi: 10.1002/cam4.4541. Epub ahead of print.
    • Genomic Correlates of Unfavorable Outcome in Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemoradiation.
    • Wei Y, Wei C, Chen L, Liu N, Ou Q, Yin JC, Pang J, Fang Z, Wu X, Wang X, Mu D, Shao Y, Yu J, Yuan S.
    • Cancer Res Treat. 2022 Jan 17. doi: 10.4143/crt.2021.963. Epub ahead of print.
    • Veliparib for the treatment of solid malignancies.
    • George RR, Thomas R, Davice A, Mathew MS.
    • J Oncol Pharm Pract. 2022 Jan 17:10781552221073990. doi: 10.1177/10781552221073990. Epub ahead of print.
    • Review
    • DNA-repair status should be assessed in treatment-emergent neuroendocrine prostate cancer before platinum-based therapy.
    • Zhu S, Zhang Z, Zhang H, Liu Z, Liu M, Liu Q, Zang L, Wang L, Ji J, Wu B, Sun L, Zhang Z, Cao H, Wang Y, Wang H, Shang Z, Niu Y.
    • Prostate. 2022 Jan 17. doi: 10.1002/pros.24292. Epub ahead of print.
    • Germline sequence variants contributing to cancer susceptibility in South African breast cancer patients of African ancestry.
    • Eygelaar D, van Rensburg EJ, Joubert F.
    • Sci Rep. 2022 Jan 17;12(1):802. doi: 10.1038/s41598-022-04791-1.
    • Breast reconstruction in patients with BRCA mutation and breast cancer - our approach.
    • Ventruba Tomáš, Brancíková Dagmar, Ventruba Pavel, Minár Luboš, Felsinger Michal, Vomela Jindrich.
    • Ceska Gynekol. 2021;86(6):374-380. English. doi: 10.48095/cccg2021374.
  • LitAlert ~~ GeneLit.com

    • Long-term tumour dormancy in a BRCA1 heterozygote.
    • Amuzu S, Fu L, Demko N, Rivera B, Domecq C, de Kock L, Hamel N, Gilbert L, Polak P, Ragoussis J, Foulkes WD.
    • J Med Genet. 2022 Jan 17:jmedgenet-2021-108269. doi: 10.1136/jmedgenet-2021-108269. Epub ahead of print.
    • Case report
    • Value of the loss of heterozygosity to BRCA1 variant classification.
    • Santana dos Santos E, Spurdle AM, Carraro DM, Briaux A, Southey M, Torrezan G, Petitalot A, Leman R, Lafitte P, kConFab Investigators, Meseure D, Driouch K, Side L, Brewer C, Beck S, Melville A, Callaway A, Revillion F, Koike Folgueira MAA, Parsons MT, Thorne H, Vincent-Salomon A, Stoppa-Lyonnet D, Bieche I, Caputo SM, Rouleau E.
    • NPJ Breast Cancer. 2022 Jan 17;8(1):9. doi: 10.1038/s41523-021-00361-2.
    • Integration of tumour sequencing and case–control data to assess pathogenicity of RAD51C missense variants in familial breast cancer.
    • Lim BWX, Li N, Rowley SM, Thompson ER, McInerny S, Zethoven M, Scott RJ, Devereux L, Sloan EK, James PA, Campbell IG.
    • NPJ Breast Cancer. 2022 Jan 17;8(1):10. doi: 10.1038/s41523-021-00373-y.
    • Bilateral Risk-Reducing Prophylactic Mastectomies in an Unaffected BRCA1 Carrier Using Dermal Sling and Implant.
    • Gupta S, Kadayaprath G, Gupta N, Barthwal V.
    • Indian J Surg Oncol. 2021 Dec;12(Suppl 2):355-358. doi: 10.1007/s13193-021-01370-0. Epub 2021 Jun 16.
    • Case report
    • Exome sequencing identifies RASSF1 and KLK3 germline variants in an Iranian multiple-case breast cancer family.
    • Radmanesh H, Liu D, Geffers R, Shandiz FH, Sadr-Nabavi A, Hillemanns P, Park-Simon TW, Dörk T.
    • Eur J Med Genet. 2022 Jan 12:104425. doi: 10.1016/j.ejmg.2022.104425. Epub ahead of print.
    • Case report
  • LitAlert ~~ GeneLit.com

    • Advocating for equitable management of hereditary cancer syndromes.
    • Caffrey RG.
    • J Genet Couns. 2022 Jan 14. doi: 10.1002/jgc4.1548. Epub ahead of print.
    • Commentary
    • Tempus, GSK Initiate Phase II Trial of Niraparib in PALB2-Mutated Tumors.
    • [No author given]
    • Precision Oncology News. Diagnostics. 2022 Jan 14.
    • Attitude towards hereditary cancer risk management among women with cancer in Taiwan.
    • Fang SY, Hsieh LL, Hung CF, Hung FH, Peng HP, Yang AS, Wang YA.
    • Support Care Cancer. 2022 Jan 14. doi: 10.1007/s00520-021-06742-4. Epub ahead of print.
    • Updates on breast biomarkers.
    • Najjar S, Allison KH.
    • Virchows Arch. 2022 Jan 14. doi: 10.1007/s00428-022-03267-x. Epub ahead of print.
    • Review
    • Spare Parts: Navigating Ovarian Cancer as a Transgender Man.
    • Bilash T, Walker LM.
    • J Clin Oncol. 2022 Jan 12:JCO2101249. doi: 10.1200/JCO.21.01249. Epub ahead of print.
    • BRCA Mutations and the Implications in Transgender Individuals Undergoing Top Surgery: An Operative Dilemma.
    • Jaber C, Ralph O, Hamidian Jahromi A.
    • Plast Reconstr Surg Glob Open. 2022 Jan 10;10(1):e4012. doi: 10.1097/GOX.0000000000004012.